Store
Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
Publication Date: April 22, 2025
Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Life Science, Mergers and Acquisitions (M&A), Oncology and Cancer
Pages: 285
SKU: 25-015KA
The Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030) report by Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge in new therapies and a promising pipeline, with significant clinical trial activity across various therapeutic areas, including oncology and cardiology.
This comprehensive report segments the market by therapeutic areas, providing detailed market estimates, forecasts, and insights into the competitive landscape. It covers global developments in cell, gene, and RNA therapy markets, focusing on key products, research trends, market breakdowns, regional revenues, and competitor analysis.
Key therapeutic areas covered include:
- Oncology
- Neurology
- Musculoskeletal
- Dermatology
- Cardiology/Non-oncology blood
- Other
The report excludes RNA therapies for COVID-19 and mRNA vaccines for infectious diseases, focusing instead on broader gene therapy applications. It also omits cord blood products, considering their classification as transplants.
Methodologically, the report combines primary and secondary research, including interviews with industry participants and comprehensive literature reviews. It provides market highlights, forecasts, and competitive analyses, discussing market indicators, trends, and barriers. Given the nascent stage of gene therapies, forecasts are based on limited precedents, with market size estimates provided for 2024 and projections through 2030.
This report serves as a crucial resource for understanding the evolving landscape of cell and gene therapies, offering valuable insights for stakeholders in the healthcare and biotechnology sectors.
Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million)
| Product Segment | 2024 | 2030 |
| Oncology | $XX Million | $XX Million |
| Neurology | $XX Million | $XX Million |
| Musculoskeletal | $XX Million | $XX Million |
| Dermatology | $XX Million | $XX Million |
| Cardio/non-oncology blood | $XX Million | $XX Million |
| Other | $XX Million | $XX Million |
| Total | $XX Million | $XX Million |
Source: Kalorama Information
COMPANION REPORT
This report is the companion to Kalorama Information’s Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021-2025 (3rd Edition), which delivers an unparalleled deep dive into the CGT market’s financial ecosystem, offering actionable insights into the deals that are driving the future of regenerative medicine.
Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021-2025 (3rd Edition) is published in two installments. The first installment, released in February 2025, covers deals up to the end of 2024. The second installment will be released in Fall 2025 and will cover deals through September 2025. Customers who purchase this third edition will receive both installments. The report covers deals including financing, funding, partnering, M&A, tech transfers, IPOs/SPACs, and other deals.
The report features:
- Investment & Funding Trends– Track quarterly funding fluctuations from Q1 2021 to Q4 2024 (volume 1) and Q1 2021 to Q3 2024 (volume 2), with a focus on venture capital, private equity, and public offerings.
- M&A and Strategic Partnerships– Understand how acquisitions, licensing agreements, manufacturing deals, and co-marketing partnerships are shaping the competitive landscape.
- Regional Market Insights– Gain a global perspective on deal activity across North America, Europe, Asia-Pacific, and emerging markets.
- Top Players & Deal-Making Trends– Identify the industry’s most active investors, biotech startups, and pharmaceutical leaders driving CGT growth.
- Regulatory & Market Challenges– Explore how regulatory shifts, reimbursement strategies, and supply chain dynamics impact CGT deal-making.
For further details and to purchase directly, please contact us.
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Potential
- Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Table 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 1-2: Global Share of Cell and Gene Therapy Market, by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 1-3: Global Share of Cell and Gene Therapy Market, by Product Segment, 2029 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
Chapter 2: Introduction to Cell and Gene Therapy
Introduction
- Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, 2022-2024, Global (count, %)
- Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, January 2025 (%)
Cell Therapy
CAR T
Stem Cells
Adult Stem Cells
Human Embryonic Stem Cells
- Table 2-2: Adult vs. Embryonic Stem Cells
Gene Therapy
- Table 2-3: Somatic vs. Germ Line Gene Therapy
Viral Vector System and New Developments
- Table 2-4: Selected Examples of Viruses in Gene Therapy
- Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
Non-viral Systems for Transporting Genes
Gene Editing
Cell and Gene Therapy: Characteristics
- Table 2-5: Cell Therapy vs Gene Therapy
Staffing
Manufacturing Process for CAR-T
Leukapheresis
Activation
Transduction
Expansion
Cell and Gene Therapy Manufacturing Processes
- Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
- Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
Cost
Reimbursement
Logistics
Mergers and Acquisitions
- Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
Deals, Agreements, and Collaborations
Regulatory Developments
Fast Track
Orphan Drug
Breakthrough Therapy
Accelerated Approval
Priority Review
- Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
Gene Therapy Approval Process
Pipeline, Development Overview
Pipeline, Development Progress
- Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), 2022-2024 (Count, %)
- Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of Q4 2024
- Table 2-10: Global Gene Therapy Pipeline, by Phase, 2022-2024 (count, %)
- Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q4 2024 (%)
Pipeline by Condition and Therapeutic Area
- Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
- Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area, Q4 2024 (%) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
- Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
- Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other]
- Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, Share Q4 2024 (%) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa]
- Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, NA/Unspecified]
- Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease, 2022-2024 (count, %) [Alzheimer’s disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson’s disease; Respiratory distress syndrome, acute; Spinal cord injury]
- Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin’s; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne’s muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington’s disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia]
- Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous]
- Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne’s muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington’s disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute]
Phase III Development
- Table 2-19: Phase III Development – Cell and Gene Therapies, Select Projects
End Users
Hospitals
Research
Wound Care Centers
Cancer Centers
Chapter 3: Cell and Gene Therapy Markets in Oncology
Overview
Biochemistry of Cancer Cells
Causes of Cancer Growth
Environmental Factors, DNA, RNA
- Table 3-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
Global Cancer Burden
- Figure 3-1: Estimated Number of New Cancer Cases, Both Sexes, Age 0-85+, All Cancers, 2020 to 2040
- Figure 3-2: Incidence of Cancer, by Type, 2020 [Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid]
- Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type, 2020 [Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers]
Market Outlook
- Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
- Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
Principal Products
Abecma
APCeden
Aucatzyl
Breyanzi
Carvykti
CreaVax-RCC
Delytact
Gendicine
Imlygic
Immuncell-LC
Kymriah
Provenge
Relma-cel
Rytelo
Tecartus
Tecelra
Yescarta
Zevor-cel
- Table 3-3: Cell and Gene Therapy in Oncology
Trends in Research and Development
Phase III Development
- Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2025
Market Breakdown of Cell and Gene Therapies
- Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type, Estimated Sales 2024 and Projected 2030 Sales ($ million) [CAR-T, Cell Immunotherapy, Gene/Oligo/Conjugate Therapy, Other Cell]
- Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [CAR-T, Cell Immunotherapy, Gene Therapy]
Oncology Cell and Gene Therapy Market by Cancer Type
- Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type, Estimated 2024 and Projected 2030 Sales ($ million) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers]
- Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
- Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
Regional Market Summary
- Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
- Figure 3-7: Oncology Cell and Gene Therapy Market, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
- Figure 3-8: Oncology Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
Competitor Summary
- Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
- Figure 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales, Estimated 2024 ($ million) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
- Figure 3-10: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2024 (%) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders
Overview
Market Outlook
- Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
- Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
Principal Products
Amvuttra
Libmeldy/ Lenmeldy
NeuroNata-R
Onpattro
SKYSONA
Spinraza
Stemirac
Upstaza
Wainua
Zolgensma
- Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2025
Market Breakdown of Cell and Gene Therapies
- Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
- Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2024 (%) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
Regional Market Summary
- Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
- Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
Competitor Summary
- Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
- Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 ($ million) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
Overview
Market Outlook
- Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
- Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
Principal Products
AlloStem
Amondys
BIO4
Carticel
Cartiform
CartiLife
Cartistem
Chondron
Elevidys
Exondys
JACC
MACI
Ortho-ACI and Ortho-ATI
Ossron
Osteocel and Osteoplus
Spherox
Trinity Elite and Trinity Evolution
Vyondys
- Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2025
Market Breakdown of Cell and Gene Therapies
- Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million)
Musculoskeletal Cell and Gene Therapy Market by Indication
- Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD]
- Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 (%) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD]
Regional Market Summary
- Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, Estimated 2024 (%) [APAC, Europe, United States, ROW]
- Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
- Figure 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
Competitor Summary
- Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2024 ($ million) [Sarepta, Vericel, Other Companies]
- Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 (%) [Sarepta, Vericel, Other Companies]
Chapter 6: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
Overview
Cardiovascular Disease
Selected Blood Disorders
Market Outlook
- Table 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
- Figure 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
Principal Products
Collategene
Hearticellgram
HeartSheet
Leqvio
Neovasculgen
Stempeucel
Zynteglo
- Table 6-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
Phase III Development
- Table 6-3: Select Cardiovascular and Blood Disorder in Phase III Cell and Gene Therapy Developments, through January 2025
Market Breakdown of Cell, Gene, and RNA Therapies
- Table 6-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
- Figure 6-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
- Table 6-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Blood, Cardiac, Hypercholesterolemia, Vascular]
Regional Market Summary
- Table 6-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
- Figure 6-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
- Figure 6-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
Competitor Summary
Chapter 7: Cell and Gene Therapy Markets in Dermatology
Overview
- Table 7-1: Wound Prevalence, by Type [Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns]
Market Outlook
- Table 7-2: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
- Figure 7-1: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
Principal Products
Adipocel
Apligraf
CureSkin
Dermagraft
Epicel
Grafix
Holoderm
Kaloderm
KeraHeal/KeraHeal-Allo
LaViv
Orcel
Quencell
RECELL
Rosmir
Stempeutics/Cutisera
StrataGraft
Stravix
TransCyte
Vyjuvek
- Table 7-3: Cell and Gene Therapy in Dermatological Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 7-4: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2025
Market Breakdown of Cell and Gene Therapies
- Table 7-5: Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
- Figure 7-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
Dermatology Cell and Gene Therapy Market by Indication
Regional Market Summary
- Table 7-6: Dermatology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 & Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
- Figure 7-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
- Figure 7-4: Dermatology Cell and Gene Therapy Market Share, by Geographic Region, 2024 (%) [APAC, Europe, North America, ROW]
Competitor Summary
- Table 7-7: Dermatology Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
- Figure 7-5: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2024 (%) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
Overview
Market Outlook
- Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
- Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
Principal Products
Alofisel
Cupistem
Givlaari
Glybera
Holoclar
Luxturna
Oxlumo
Rethymic
Ryoncil/ Prochymal/ Temcell
Tryngolza
- Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders
Trends in Research and Development
Market Breakdown of Cell and Gene Therapies
- Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
- Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
Regional Market Summary
- Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
- Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
- Figure 8-4: Other Conditions Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [Europe, North America, ROW]
Competitor Summary
Chapter 9: Cell and Gene Therapy Market Review
Market Influences
Global Demographics
- Table 9-1: Global Population, 1980-2050 (population in millions)
Aging Population
- Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cost Containment
- Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
Cell and Gene Therapy and Viral Vector Shortages
Global Market Summary
- Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/non-oncology blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-2a: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-2b: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales by Disease Segment, 2024 [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
Cell vs. Gene Therapy Markets
- Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method, 2024-2030 ($ million)
- Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2024 (%)
- Figure 9-5: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2029 (%)
Regional Market Overview
- Table 9-5: Cell, Gene, & RNA Therapy Market Summary by Geographical Region, 2024-2030 ($ million) [Europe, North America, ROW]
North America
- Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Table 9-7: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-6: U.S. Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Table 9-8: Major Cell and Gene Therapy Product Approvals, FDA
Europe/European Union
- Table 9-9: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-7: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-8: Europe Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Table 9-10: Major Cell and Gene Therapy Approvals by EMA
Other Countries
- Table 9-11: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-9: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Figure 9-10: ROW Cell, Gene, & RNA Therapy Market, Distribution by Disease Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
- Table 9-12: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
Competitor Ranking in Cell and Gene Therapy Markets
- Table 9-13: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
- Figure 9-11: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
- Figure 9-12: Cell and Gene Therapy Market Share Estimates by Leading Competitors, 2024 (%) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
Chapter 10: Market Participants
Leading Influencers
AlloSource
- Table 10-1: AlloSource Corporate Summary
Company Summary
Products
Alnylam Pharmaceuticals, Inc.
- Table 10-2: Alnylam Pharmaceuticals Corporate Summary
Company Summary
Products
Amgen
- Table 10-3: Amgen Corporate Summary
Company Summary
Products
AnGes Inc.
- Table 10-4: AnGes Corporate Summary
Company Summary
Products
Anterogen Co Ltd.
- Table 10-5: Anterogen Corporate Summary
Company Summary
Products
Atara Biotherapeutics
- Table 10-6: Atara Biotherapeutics Corporate Summary
Company Summary
Products
BioCardia
- Table 10-7: BioCardia Summary
Company Summary
Products
Projects in the pipeline using the CardiAMP system include:
Projects in the pipeline using the CardiALLO system include:
Biogen, Inc.
- Table 10-8: Biogen Corporate Summary
Company Summary
Products
BioMarin Pharmaceuticals
- Table 10-9: BioMarin Pharmaceuticals Corporate Summary
Company Summary
Products
bluebird bio, Inc.
- Table 10-10: bluebird bio Corporate Summary
Company Summary
Products
BrainStorm Cell Therapeutics
- Table 10-11: BrainStorm Cell Therapeutics Corporate Summary
Company Summary
Products
Bristol-Myers Squibb
- Table 10-12: Bristol-Myers Squibb Corporate Summary
Company Summary
Products
Candel Therapeutics
- Table 10-13: Candel Therapeutics Corporate Summary
Company Summary
Products
In the pipeline, the company offers:
Castle Creek Biosciences
- Table 10-14: Castle Creek Corporate Summary
Company Summary
Products
Celyad Oncology
- Table 10-15: Celyad Oncology Corporate Summary
Company Summary
Products
Cook Myosite, Inc
- Table 10-16: Cook Myosite Corporate Summary
Company Summary
Products
Dendreon Pharmaceuticals (Sanpower)
- Table 10-17: Dendreon Corporate Summary
Company Summary
Products
Ferring Pharmaceuticals
- Table 10-18: FerGene Corporate Summary
Company Summary
Products
Gamida Cell Ltd.
- Table 10-19: Gamida Cell Corporate Summary
Company Summary
Products
GenSight Biologics S.A.
- Table 10-20: GenSight Biologics Corporate Summary
Company Summary
Products
Gilead Sciences, Inc.
- Table 10-21: Gilead Sciences Corporate Summary
Company Summary
Products
Other selected indications in the pipeline include:
Gradalis, Inc
- Table 10-22: Gradalis Corporate Summary
Company Summary
Products
Helixmith
- Table 10-23: Helixmith Corporate Summary
Company Summary
Products
Inovio Pharmaceuticals, Inc.
- Table 10-24: Inovio Pharmaceuticals Corporate Summary
Company Summary
Products in the Pipeline
Medeor Therapeutics
- Table 10-25: Medeor Therapeutics Corporate Summary
Company Summary
Products
MEDIPOST Co, Ltd.
- Table 10-26: MEDIPOST Corporate Summary
Company Summary
Products
MeiraGTx
- Table 10-27: MeiraGTx Corporate Summary
Company Summary
Products
Mesoblast Ltd.
- Table 10-28: Mesoblast Corporate Summary
Company Summary
Products
Northwest Biotherapeutics, Inc.
- Table 10-29: Northwest Biotherapeutics Corporate Summary
Company Summary
Products
Novartis AG
- Table 10-30: Novartis Corporate Summary
Company Summary
Products
Other Current Projects
NuVasive Biologics
- Table 10-31: NuVasive Biologics Corporate Summary
Company Summary
Products
Orchard Therapeutics
- Table 10-32: Orchard Therapeutics Corporate Summary
Company Summary
Products
Organogenesis
- Table 10-33: Organogenesis Corporate Summary
Company Summary
Products
Orthofix
- Table 10-34: Orthofix Corporate Summary
Company Summary
Products
Osiris Therapeutics, Inc. (Smith & Nephew)
- Table 10-35: Osiris Corporate Summary
Company Summary
Products
Pharmicell
- Table 10-36: Pharmicell Corporate Summary
Company Summary
Products
Pluristem Therapeutics, Inc.
- Table 10-37: Pluristem Therapeutics Corporate Summary
Company Summary
Products
Sangamo Therapeutics
- Table 10-38: Sangamo Therapeutics Corporate Summary
Company Summary
Products
Sanofi
- Table 10-39: Sanofi Corporate Summary
Company Summary
Sarepta Therapeutics
- Table 10-40: Sarepta Corporate Summary
Company Summary
Products
Sotio a.s.
- Table 10-41: Sotio Corporate Summary
Company Summary
Products
Spark Therapeutics
- Table 10-42: Spark Therapeutics Corporate Summary
Company Summary
Products
Pipeline Projects
uniQure N.V.
- Table 10-43: uniQure Corporate Summary
Company Summary
Products
Vericel Corporation
- Table 10-44: Vericel Corporate Summary
Company Summary
Products
Related products
IVD Market Trends Report, March 2023
March 17, 2023
Diagnostic testing remains a cornerstone in healthcare, aiding physicians in diagnosis and providing crucial information for treatments like precision medicine. As we navigate the aftermath of the COVID-19 pandemic, the IVD market is evolving, driven by new products, shifts in global health spending, regulatory updates, and changing disease trends. Despite these shifts, the IVD market…
Price range: $3,000.00 through $4,500.00
In Vitro Diagnostic (IVD) Trends and Market Update: November 2023
November 7, 2023
As in vitro diagnostic (IVD) testing returns to its vital role in healthcare, it remains a cornerstone in medical practice, providing crucial insights for physicians, from diagnosis to precision medicine. While COVID-19 testing sees a decline, it continues to influence total revenues for 2023. In this ever-changing landscape, characterized by new products, shifts in global…
Price range: $3,750.00 through $5,625.00
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
